Literature DB >> 16897113

LPS-stimulated production of TNF-alpha by peripheral blood monocytes in patients with Behcet's disease.

Gleb Slobodin1, Yazeed Toukan, Itzhak Rosner, Michael Rozenbaum, Nina Boulman, Elsa Pavlotzky, Aharon Kessel, Elias Toubi.   

Abstract

Tumor necrosis factor alpha (TNF-alpha) is believed to play a significant role in disease pathogenesis of Behcet's disease (BD). High serum levels of TNF-alpha were repeatedly reported in patients with active BD and anti-TNF agents are effective in its treatment. The pathophysiology of TNF-alpha in BD is still unknown and conflicting results regarding TNF-alpha overproduction by peripheral blood monocytes (PBM) from patients with BD were reported. The aim of the study is to compare stimulated production of TNF-alpha by PBM of BD patients with that of healthy volunteers (HV) and to examine correlations between the ability of PBM to produce TNF-alpha and organ/system involvement in patients with BD. Eighteen patients with BD (mean age 38.4+/-12.4 years, 12 males) gave informed consent and completed the European BD Current Activity Form. The PBM were separated and treated with lipopolysaccharide (LPS) overnight. TNF-alpha levels in the supernatants were assayed by ELISA and values were expressed in terms of cell protein contents. The control group included 15 HV (mean age 34.2+/-9.9 years, seven males). The mean production of TNF-alpha/cell protein (ng/mg) and in-group dispersion were similar in both groups (p=0.98). In the subgroup analysis, TNF-alpha production by PBM in BD patients who reported "bad" or "very bad" global well-being over the last month (n=4) was higher compared to other patients with better self-rating (p=0.03). PBM of BD patients in the present study did not overproduce TNF-alpha upon stimulation with LPS. However, BD patients with a higher TNF-alpha-producing capacity had worse sense of well-being.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16897113     DOI: 10.1007/s10067-006-0371-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

1.  Production of TNF-alpha and IL-1 in active Behçet's disease.

Authors:  K Hamzaoui; M Hamza; K Ayed
Journal:  J Rheumatol       Date:  1990-10       Impact factor: 4.666

Review 2.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

Review 3.  New approaches in the treatment of Adamantiades-Behçet's disease.

Authors:  Nicolò Pipitone; Ignazio Olivieri; Fabrizio Cantini; Giovanni Triolo; Carlo Salvarani
Journal:  Curr Opin Rheumatol       Date:  2006-01       Impact factor: 5.006

4.  Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects.

Authors:  J L Mege; N Dilsen; V Sanguedolce; A Gul; P Bongrand; H Roux; L Ocal; M Inanç; C Capo
Journal:  J Rheumatol       Date:  1993-09       Impact factor: 4.666

5.  Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease.

Authors:  M O Oztas; M Onder; M A Gurer; N Bukan; B Sancak
Journal:  Clin Exp Dermatol       Date:  2005-01       Impact factor: 3.470

6.  Cytokine production profile in patients with Behcet's disease treated with infliximab.

Authors:  Midori Misumi; Eri Hagiwara; Mitsuhiro Takeno; Yukiko Takeda; Yuko Inoue; Takashi Tsuji; Atsuhisa Ueda; Satoshi Nakamura; Shigeaki Ohno; Yoshiaki Ishigatsubo
Journal:  Cytokine       Date:  2003-12-07       Impact factor: 3.861

Review 7.  Genetic determinants of the inflammatory response.

Authors:  Scott D Imahara; Grant E O'Keefe
Journal:  Curr Opin Crit Care       Date:  2004-10       Impact factor: 3.687

8.  Tumour necrosis factor-alpha gene promoter region -308 and -376 G-->A polymorphisms in Behçet's disease.

Authors:  J Duymaz-Tozkir; A Gül; F A Uyar; U Ozbek; G Saruhan-Direskeneli
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

9.  The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement.

Authors:  Yavuz Bardak; Buket Cicioğlu Aridoğan
Journal:  Ocul Immunol Inflamm       Date:  2004-03       Impact factor: 3.070

10.  Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.

Authors:  Cem Evereklioglu; Hamdi Er; Yusuf Türköz; Mustafa Cekmen
Journal:  Mediators Inflamm       Date:  2002-04       Impact factor: 4.711

View more
  5 in total

1.  A Short Peptide That Mimics the Binding Domain of TGF-β1 Presents Potent Anti-Inflammatory Activity.

Authors:  Emília R Vaz; Patrícia T Fujimura; Galber R Araujo; Carlos A T da Silva; Rangel L Silva; Thiago M Cunha; Mônica Lopes-Ferreira; Carla Lima; Márcio J Ferreira; Jair P Cunha-Junior; Ernesto A Taketomi; Luiz R Goulart; Carlos Ueira-Vieira
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

2.  Novel Insights Into Gene Signatures and Their Correlation With Immune Infiltration of Peripheral Blood Mononuclear Cells in Behcet's Disease.

Authors:  Haoting Zhan; Haolong Li; Linlin Cheng; Songxin Yan; Wenjie Zheng; Yongzhe Li
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

Review 3.  Trained Immunity Contribution to Autoimmune and Inflammatory Disorders.

Authors:  Samanta C Funes; Mariana Rios; Ayleen Fernández-Fierro; María S Di Genaro; Alexis M Kalergis
Journal:  Front Immunol       Date:  2022-04-08       Impact factor: 8.786

Review 4.  The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders.

Authors:  Rob J W Arts; Leo A B Joosten; Mihai G Netea
Journal:  Front Immunol       Date:  2018-02-20       Impact factor: 7.561

Review 5.  Understanding Behçet's Disease in the Context of Innate Immunity Activation.

Authors:  Sandro F Perazzio; Luis E C Andrade; Alexandre W S de Souza
Journal:  Front Immunol       Date:  2020-10-20       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.